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Open access under CCThe reduction in human immunodeﬁciency virus (HIV) infection in
women demonstrated by pericoital use of tenofovir gel has
encouraged the continued development of microbicides. Novel
approaches include new ways to deliver tenofovir, as well as
products that contain different antiretroviral drugs, either as single
agents or as combinations of antiretroviral drugs. Indeed,
emphasis has renewed on the development of multipurpose
prevention technologies, products designed to address multiple
sexually transmitted infections. Dual-purpose contraceptive anti-
retroviral products are also being designed to prevent HIV and
pregnancy. Since consistent and correct use of these products will
be critical to their effectiveness, the active pharmaceutical ingre-
dients must be delivered in acceptable vaginal dosage forms, such
as gels, ﬁlms and sustained-release vaginal rings. The development
of different dosage forms will help ensure that women can ﬁnd
a method to protect themselves from HIV, pregnancy, and poten-
tially other sexually transmitted infections.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
A proof-of-concept for human immunodeﬁciency virus (HIV) prevention by antiretroviral (ARV)-
based microbicides was achieved when 1% tenofovir gel was found to reduce the HIV infection rate by
39% in women using the gel up to 12 h before sex and again within 12 h after sex, compared with
women using a placebo gel.1 It is evident that this approach to prevention has the potential to
transform the response to the HIV and acquired immune deﬁciency syndrome (AIDS) pandemic.
Further research, however, is needed on vaginal microbicides, including studies of different dosingax: þ1 301 608 2241.
. Rosenberg).
 BY-NC-ND license.
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targets in the HIV infection process, in order to build upon the level of effectiveness observed with
tenofovir gel.
The successful development of vaginally applied products for the prevention of HIV infection
requires signiﬁcant levels of protection against HIV acquisition, demonstrated safety in healthy pop-
ulations, and no adverse interactions with commonly used vaginal drugs or other HIV prevention
approaches. Approaches to the vaginal delivery of microbicides have been based on products used to
deliver drugs for the treatment of vaginal infections, contraception and hormone replacement, as well
as oral personal care products. These delivery systems commonly include semi-solid gels and creams,
intravaginal rings, fast-dissolving ﬁlms, tablets and capsules, foams and suppositories.2,3 The two
dosage forms most commonly used in the development of candidate microbicides are shown in Fig. 1.
A product’s effectiveness will depend on its consistent use, therefore, the design of formulations that
women ﬁnd routinely easy to use is of paramount importance in microbicide development. Demo-
graphic characteristics such as age, socioeconomic status and culture, among others, will all play a role
in a microbicide’s acceptability in any given population, similar to that seen for contraceptives. Data
from amarket research study in several countries in Africa4 suggest that the availability of microbicides
in multiple dosage forms may increase acceptability, adherence and, therefore, effectiveness.
The development of an effective microbicide for HIV prevention involves the selection of potent
drugs that can interfere with HIV replication and delivering the drug to the site of replication at the
appropriate time. Thus, both the drug and the drug-delivery system are crucial components of
a successful product. The physical and chemical properties of ARV-based compounds allow for their
delivery in formulations designed for ﬂexible dosing, including daily or monthly use, in addition to
coitally related application. In this chapter, we will review the ARVs and the most common vaginalFig. 1. a - Vaginal applicator containing gel. b - Vaginal ring.
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development for multiple indications, including contraception and other sexually transmitted
infections.
Microbicides in clinical development
Dapivirine
Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) originally developed as an
oral therapeutic before being selected for microbicide evaluation owing to poor bioavailability.5,6
Dapivirine is speciﬁc for, and binds directly to, HIV-1 reverse transcriptase, thereby blocking reverse
transcriptase activity and preventing HIV-1 replication. Multiple in vitro studies have shown that
dapivirine is able to inhibit both cell free- and cell-associated HIV-1 infection.7,8 Dapivirine is also able
to inhibit direct infection of mucosal tissue in human cervical explant cultures and to prevent spread of
virus by migratory cells. Inhibition of virus by dapivirine was not signiﬁcantly affected by the presence
of either semen or cervical mucus stimulant.9 Dapivirine has potent activity against a wide range of
NNRTI-resistant isolates compared with nevirapine, delavirdine, efavirenz and emivirine.8–10 In severe
combined immunodeﬁcient mouse-human mice reconstituted with human peripheral blood
lymphocytes, application of dapivirine gel was able to block vaginal infection with both CCR5 and
CCR5/CXCR4-infected cells.11
Dapivirine gels
Given the long history of use of gels as vaginal delivery dosage forms,3,12 gel formulations of
dapivirine were developed and evaluated pre-clinically and clinically. Dapivirine gels have shown good
safety proﬁles in rabbit vaginal irritation studies of up to 39 weeks duration, in in vitro and in vivo
mutagenicity studies, and in reproductive toxicity studies in rats and rabbits13,14 (Nuttall J, personal
communication).
Results from pharmacokinetic and safety studies of dapivirine vaginal gels in healthy, HIV-negative
women6,15–17 showed good distribution of dapivirine in the lower genital tract with low systemic
absorption. The gels were safe and well tolerated, with no differences in side-effects between dapi-
virine gel and matching or universal placebo gel groups. Concentrations of dapivirine in the genital
tract were approximately 4–5 logs higher than the 50% inhibitory concentration against HIV-1 in vitro
and 3 logs higher than plasma concentrations after oral dapivirine administration, which resulted in at
least a 10-fold reduction in viral load.
Dapivirine vaginal rings
Vaginal rings are devices designed to provide sustained delivery of drugs to the vagina for either
local or systemic effect. The ﬁrst ring product to reach the market in 1993 was Estring, a silicone
elastomer reservoir device providing release of 7.5 mg 17-b-estradiol daily over 3 months for the local
treatment of menopausal urogenital atrophy.18 Two other rings have also been licensed for use;
Nuvaring, an ethylene vinyl acetate ring delivering the contraceptive steroids etonogestrel and
ethinylestradiol over 21 days, and Femring (Menoring in the UK), a silicone ring delivering a 3-
month dose of an estradiol prodrug, estradiol-3-acetate.18
For vaginal rings to be suitable for microbicide delivery in women who are at risk of HIV, the
physical presence of the vaginal ring should not cause deleterious effects on the local vaginal and
cervical epithelium. After a report of chronic erythematous and ulcerative lesions in the posterior
vaginal fornix with an early prototype contraceptive ring,19 several studies examining the local clinical
safety of vaginal rings have shown few, if any, adverse effects (including clinical lesions and vaginal
ﬂora changes) attributable to the presence of the ring itself.20–22 Minor colposcopic ﬁndings have been
reported, with most resolving despite continued use of the ring. The incidence of ulcerations, abrasions
and ecchymoses greater than 0.5 cm, or ﬁeld of ﬁve or more petechiae, was not statistically different
between ring users and sexually active historical controls.21,23 In a recent safety and acceptability study
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treatment observation period or vice versa, adverse events occurred with similar frequency in the
treatment and observation periods (Nel A, personal communication).
Several dapivirine vaginal rings have been developed using different polymers and manufacturing
processes.24–29 The initial dapivirine vaginal rings evaluated clinically contained either 25 mg or
200 mg dapivirine in a tin-catalysed silicone reservoir ring, containing a central drug-ﬁlled core
enclosed by an non-medicated outer ring.27,30 The vaginal rings were found to be safe and well
tolerated, successfully delivering the drug in vaginal ﬂuids and tissue in the vagina and cervix, with low
systemic absorption. Concentrations of dapivirine throughout the lower genital tract were greater than
three logs higher than the in vitro EC 50.
A subsequent study compared a tin-catalysed dapivirine reservoir vaginal ring to a matrix-type
conﬁguration, in which the drug is uniformly distributed throughout the silicone.29,30 Similar to the
reservoir ring, the dapivirine matrix vaginal ring had a good safety proﬁle with low systemic exposure
and high concentrations of drug throughout the lower genital tract. A platinum-catalysed silicone ring
(Ring-004), designed to improve stability, has been evaluated in phase I and phase II clinical studies
involving more than 300 women, and has conﬁrmed the good safety and a pharmacokinetic proﬁles of
earlier prototypes (Nel A, personal communication).
The ability of vaginal rings to release the drug over prolonged periods of time allows for a monthly
(or less frequent) dosage form that may contribute to greater consistency in product use.31 Studies
assessing the acceptability of vaginal rings for contraception showed that they can be successfully used
by women. Favourable characteristics most often reported by women in these studies included indi-
vidual control over ring insertion and removal; not needing to remember to take a daily pill; and
comfort and ease of use.20,32–35 Compared with other contraceptive dosage forms (oral pills and skin
patches), women reported convenience, frequency of use and lower risk of unintentional non-use as
being the primary reasons for choosing the vaginal ring.36–38 A pattern of more consistent use is
supported by the results from a cross-sectional multicentre study of 26,250 typical users of a combined
hormonal contraceptive showing that emergency contraceptionwas requested by 14% of pill users, 11%
of patch users and 6.3% of ring users.39
More recently, several studies have been conducted in an effort to determine the acceptability of
vaginal rings for HIV prevention in populations at high risk of HIV infection, speciﬁcally in sub-Saharan
Africa. In a study of attitudes towards hypothetical use of vaginal rings among female sex workers and
their clients in Kenya, perceived beneﬁts of vaginal ring use included a lack of required preparation and
inhibition of sexual spontaneity, and compatibility with dry sex preferences. Potential concerns
included comfort, detection bymale partner, and vaginal hygiene during prolonged use.40 Acceptability
during actual use of a placebo vaginal ring in a clinical safety and acceptability study in South Africa and
Tanzania was high, with most women reporting that the ring was comfortable, easy to insert and
remove, and could be used without male partner knowledge. A minority of women were concerned
about the ring getting lost within the body or being expelled (Woodsong C, personal communication).
Given its ease of use, stability for more than 2 years in zone 4 conditions (30 C and 65% relative
humidity), and relatively lowmanufacturing cost, dapivirine ring-004, if safe and effective against HIV,
would be suitable for use in developing countries, especially in sub-Saharan Africa where HIV inci-
dence in women is high. Randomised, placebo-controlled studies to determine efﬁcacy and long-term
safety of dapivirine ring-004 in about 5000 women are planned to begin in several countries in sub-
Saharan Africa in early 2012. Additional studies evaluating safety in adolescents and peri-
menopausal and post-menopausal women are also planned.
Dapivirine ﬁlm
Dapivirine has also been formulated into small fast-dissolving ﬁlms, designed to release drug
following dissolution by vaginal ﬂuids.41 Flexible, translucent polyvinyl alcohol-based vaginal ﬁlms
containing 1.25 mg dapivirine per ﬁlmwere designed to dissolve rapidly upon exposure to an aqueous
environment with greater than 50% of the loaded dapivirine being released from the ﬁlm within
10mins. In addition, dapivirinewas shown to permeate target tissue in vitro and inactivate HIV-1 in ex-
vivo models using human cervical explant tissue.41 The advantages of vaginal ﬁlms as a microbicide
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especially for hydrophobic drugs such as dapivirine. As a result of their small size, vaginal ﬁlms may
also have economic advantages over vaginal rings and gels in manufacturing, storage and shipping
costs. Vaginal leakage observedwith frequent use ofmicrobicide gels may also be eliminated by vaginal
ﬁlms that do not require exogenous ﬂuids for dissolution.3,18 Acceptability of vaginal ﬁlms as
a contraceptive dosage form has been evaluated in several studies that reported similar levels of
satisfaction for vaginal ﬁlms compared with contraceptive gels, foams and suppositories.42,43 Women
have also reported acceptability of vaginal ﬁlms for microbicide delivery.4,44–46
Maraviroc
Maraviroc, belongs to a pharmacological class of antiretroviral agents known as CCR5 antagonists,
marketed as Selzentry (Pﬁzer Labs, New York, NY, USA) for treatment of CCR5-tropic HIV-1 infection,
which acts by blocking the CCR5 co-receptor on human cellular targets to prevent infection of the cell
by HIV-1.47,48 As CCR5 is the primary co-receptor involved in sexual transmission of HIV, blocking CCR5
has the potential to prevent the establishment of infection in individuals exposed to the virus.49
Maraviroc has demonstrated efﬁcacy in vitro against a wide range of CCR5-tropic clinical isolates
from multiple clades of HIV-1, as well as those resistant to other classes of antiretroviral medicinal
products.47 Maraviroc delivered vaginally has been shown in non-human primates (NHP) to prevent
transmission of simian human immunodeﬁciency virus (SHIV) infection when delivered within a few
hours before infection.50
Maraviroc and maraviroc-dapivirine vaginal rings
Maraviroc’s short duration of effect in NHP suggests that vaginal rings would be a suitable dosage
form for maraviroc-based microbicides. Pre-clinically, maraviroc has been shown to be safe after
topical gel application for 4 weeks in rabbit vaginal irritation studies (Nuttall J, personal communi-
cation). Vaginal rings containing maraviroc, and a combination of maraviroc and dapivirine, are
currently being tested in a phase I safety and pharmacokinetics study (Hillier S, personal communi-
cation). Although maraviroc is a licensed therapeutic, a signiﬁcant body of data support the safety of
maraviroc delivered orally. This is the ﬁrst clinical study utilizing maraviroc in women for vaginal use.
Themaraviroc vaginal ring contains 100mg of maraviroc, and the combination vaginal ring contains an
additional 25 mg dapivirine, dispersed in a platinum-catalysedcured silicone matrix. In vitro, similar
amounts of each drug are released from the vaginal rings over a 28-day period despite the four-fold
difference in initial concentration, suggesting a lower solubility of maraviroc in silicone (Devlin B,
personal communication). The rationale for developing microbicides containing combinations of ARVs
is discussed later in this chapter.
Tenofovir vaginal ring, ﬁlm and tablet
Tenofovir (Viread, Gilead Sciences, Inc.) is a nucleotide reverse transcriptase inhibitor approved for
the treatment of HIV infection.51 In addition to 1% tenofovir gel, currently being tested in a phase III
conﬁrmatory efﬁcacy trial for coitally associated use, other dosage forms of tenofovir are also under
development.52 A polyurethane-based tenofovir vaginal ring, designed to release at least 10 mg
tenofovir daily over several months to help improve adherence, is planned to enter phase I clinical
testing in 2012. Additional formulations in development include a fast-dissolving ﬁlm and tablet,
which both have potential economic and acceptability advantages over the gel dosage form.
Additional candidates in development
MIV-150
Like dapivirine, MIV-150 is a tightly-binding NNRTI with potent activity in vitro against awide range
of clinical isolates of HIV and a favourable resistance proﬁle.5,53 Under development by the Population
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challengewith a SHIV-RTwhen applied topically 30mins before vaginal challenge.54 Although 2weeks
of daily application of 50 M MIV-150 protected over 50% of macaques from infection for up to 8 h after
last use, the combination of low dose MIV-150 and zinc acetate provided complete protection from
infection for at least 24 h.55
DS 003
DS 003 (originally designated BMS-599793) is a highly potent molecule, one of a series of entry
inhibitors discovered at Bristol Myers Squibb that binds tightly to the viral envelope glycoprotein
gp120.56–58 This binding likely interferes with the interaction of HIV gp120 with the CD4 receptor on
the host cell and prevents initial virus attachment. By acting at the earliest time of viral exposure,
before interaction with its target cells, gp120 inhibitors have a strong potential to inhibit initial viral
infection as vaginally delivered microbicides.59 One compound of this class, Bristol Myers Squibb
-378806 (Bristol Myers Squibb -806), has been shown to neutralise a broad range HIV-1 clades and
subtypes with minimal cytotoxicity.56 Bristol Myers Squibb -806 has also been shown to protect
macaques against vaginal SHIV challenge.60
Licensed by Bristol Myers Squibb to the International Partnership for Microbicides in 2005 to
develop into a microbicide for global use, DS003 has also been shown to broadly neutralise HIV-1 as
well as viral infection of ex vivo genital explants with much higher potency than Bristol Myers Squibb-
806. Preliminary studies indicate that DS003 has no genotoxicity, no evidence of sensitisation in guinea
pigs, and no local or systemic toxicity in either rats or rabbits at intravaginal doses up to 25% weight/
weight (Nuttall J, personal communication). Given its mechanism of action, DS003 will need to be
active in the aqueous environment of the vagina to prevent HIV transmission. Strategies for optimal
delivery of DS003 are current in development.
Integrase and protease inhibitors
Although acting relatively late in the HIV life cycle, integrase inhibitors represent another possible
class of ARVs that could be delivered vaginally for HIV prevention.61 Although a number of potential
drugs exist as licensed HIV therapeutics or in late-stage therapeutic development (e.g. raltegravir, and
elvitegravir),62,63 relatively little preclinical development is under way.
Protease inhibitors are another potential class of ARVs to be considered for topical prophylaxis.
Protease inhibitors act to prevent HIV maturation late in the viral life cycle; however, after pro-viral
DNA integration, this class of compounds will likely need to be coformulated with drugs acting at
pre-integration steps. The potential role for protease inhibitors in prevention rests on data that suggest
that establishment of infection of mucosal tissue stems from viral dissemination from a small foci of
infected cells.64 Preclinical studies of protease inhibitors in tissue explant models and in NHP are
ongoing.
Combination microbicides
Antiretroviral agents delivered in combination have been shown to be highly effective for the
treatment of HIV infection as well as in the prevention of mother-to-child transmission of HIV.65 The
rationale for a combination microbicide is based on the evidence that two or more ARVs present
a greater barrier to infection than a single drug against circulating transmitted HIV strains that may be
drug resistant, especially as resistant viruses may be transmitted less efﬁciently than wild-type HIV.66
Combinationmicrobicidesmay have greater potency than products with single agents, as they have the
potential to block HIV infection at multiple steps in the HIV replication pathway.
As described earlier in the chapter, several microbicides that deliver a combination of drugs,
including dapivirine and maraviroc, as well as MIV 150 and zinc acetate, are currently in development
as microbicides.3,29,52,67 Some beneﬁts of combining dapivirine and maraviroc potentially include
activity against NNRTI-resistant strains, R5 HIV-2 viruses and rare transmission events with CXCR4
virus.68,69 Preclinical development of combinations of protease inhibitors with ARVs that act earlier in
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efﬁcacy. Such combinations may also increase the barrier to the possible development of resistance
should a microbicide be used by an HIV-infected individual, although it is not known if the low ARV
plasma concentrations observed following microbicide use would select for resistant virus.31
Efforts are also under way to develop combination vaginal rings containing tenofovir and dapivirine
using a polyurethane polymer system, owing to its versatility in allowing release of hydrophilic and
hydrophobic drugs.3,28,67,70 A recent in vitro study suggests that the combination of dapivirine and
tenofovir results in synergy against subtype C NNRTI-resistant HIV-1.71 Another approach to increasing
the efﬁcacy of tenofovir for HIV prevention is a combination with acyclovir to prevent herpes simplex
virus (HSV)-2 infection.72 A polyurethane vaginal ring containing 10% tenofovir and 10% acyclovir has
been developed that can release both drugs for up to 1 month. A second tenofovir and acyclovir
coformulation effort involves a silicone-based ring containing individual drug cores that release drug at
independent rates.52 Combination microbicides in development for the prevention of HIV infection in
women through sexual transmission are presented in Table 1. As discussed above, most combination
microbicides are currently in preclinical development, with the exception of the dapivirine and mar-
aviroc combination ring, which began clinical testing in 2011.Contraceptive microbicides
Effective forms of contraception are important reproductive health interventions for women in
developing and developed countries, and hormone-based products are available in various dosage
forms.73 A product that is able to protect against HIV and provide reliable contraception, therefore, has
the potential to have important health beneﬁts, particularly in sub-Saharan Africa where the effect of
the HIV epidemic is felt most. To address this need, dual-purpose contraceptive microbicides are being
developed (Table 2). One such product is a vaginal ring that contains both an ARV (tenofovir) and
levonorgestrel, a synthetic contraceptive hormone, originally shown to have contraceptive efﬁcacy
when released from a silicone vaginal ring.74 To solve a three-log difference in release rates of the two
active drugs, a two-segment polyurethane vaginal ring was designed, similar to one designed for the
co-delivery of tenofovir and dapivirine.70 Clinical testing is expected to begin in 2012.
The development of a dapivirine contraceptive vaginal ring is also in progress. Multiple hormones
are being screened with dapivirine to determine appropriate combinations of active pharmaceutical
ingredients for this multipurpose prevention product. The hormones that will be tested in combinationTable 1
Combination microbicides in development for human immunodeﬁciency virus prevention.
Mechanism of action Early preclinical Late preclinical Clinical – phase I
NRTI þ HSV-2 blocker Tenofovir/acyclovir (CONRAD)b
NRTI þ protease inhibitor Tenofovir/darunavir (CHAARM)a
NRTI þ gp120 inhibitor Tenofovir/DS003 (IPM)a
NRTI þ CCR5 blocker Tenofovir/maraviroc (IPM)c
NNRTI þ zinc MIV-150/zinc acetate (PC)a,b
NRTI þ NNRTI Tenofovir/dapivirine
(CONRAD/IPM)b
NNRTI þ protease inhibitor Dapivirine/darunavir (CHAARM)a,b
NNRTI þ gp120 inhibitor Dapivirine/DS003 (IPM)d
NNRTI þ CCR5 blocker Dapivirine/maraviroc (IPM)a Dapivirine
/maraviroc (IPM)b
Product developers or sponsors are listed in parentheses: CHAARM, Combined Highly Active Anti-Retroviral Microbicides
European Union-supported collaborative project; IPM, International Partnership for Microbicides; PC, Population Council; CCR5,
chemokine receptor type 5; gp120, glycoprotein 120; HSV, herpes simplex virus.
Formulation:
a Vaginal gel.
b Vaginal ring.
c Vaginal ﬁlm.
d Vaginal tablet.
Table 2
Dual-purpose products in development for human immunodeﬁciency virus prevention and contraception.
Active pharmaceutical ingredient Mechanism of action Formulation Stage of development
Tenofovir/levonorgestrel NRTI plus hormonal contraceptive Vaginal ring Late preclinical
Dapivirine/levonorgestrel NNRTI plus hormonal contraceptive Vaginal ring Early preclinical
MIV-150/levonorgestrel NNRTI plus hormonal contraceptive Vaginal ring Early preclinical
SILCS diaphragm/tenofovir NRTI plus barrier device Diaphragm with gel Early preclinical
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
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were chosen because they are off patent, commercially available, and there is some experience with
these active pharmaceutical ingredients in vaginal rings. Second-generation progestins, such as levo-
norogestrol and norethindrone-acetate, are also being considered for evaluation (Devlin B, personal
communication). Similarly, vaginal rings containing MIV-150, zinc acetate, and a contraceptive are
being studied.75
Potential dual-purpose, non-hormonal contraceptives include the single-size SILCS diaphragm76
containing tenofovir gel. Given the results of in vitro and in vivo data showing that tenofovir gel ini-
hibits HSV-2 transmission,1,77 a tenofovir-containing SILCS diaphragm may provide coitally associated
contraception and prevent HIV and HSV-2.52 Efforts to develop a sustained dapivirine-releasing SILCS
diaphragm are also under way (Devlin B, personal communication).
Conclusion
Human immunodeﬁciency virus and AIDS is one of the greatest threats to women’s health, and
women urgently need self-initiated, practical tools to protect themselves. Building upon the ground-
breaking results from the CAPRISA 0041 study demonstrating efﬁcacy of tenofovir gel, a number of
highly potent ARVs are being developed in novel dosage forms. The pipeline of ARVs for microbicide
development includes drugs that attack HIV at different stages of the viral replication cycle. Combi-
nations of ARVs with different mechanisms of action are being considered to increase the potential
level of efﬁcacy and reducing the theoretical risk of transmission by ARV resistant virus. A variety of
dosage forms are being developed to allow for more product options as, the more product options
women have access to, the more likely they are to be able to use at least one. The microbicide vaginal
ring offers promising advantages, including its long-acting duration, versatility in dosing, and the
potential to deliver combinations of ARV drugs or an ARV drug along with a contraceptive, which
would allow women to preserve their HIV prevention and reproductive choices. Fast-dissolving ﬁlms
and tablets may be economically viable options, and address stability challenges posed by particular
drugs. Vaginal rings and other female-initiated HIV prevention products promise to empower women
with the tools they need to protect their health and, in turn, that of their families and communities.
Research agenda Validation of in vitro and in vivo animal models for microbicide safety and efﬁcacy.
 Correlation of tissue drug concentrations with HIV protection.
 Determination of risk of selection for drug resistance by use of vaginal microbicides.References
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